Evaluation of glycomic profiling as a diagnostic biomarker for epithelial ovarian cancer

Autor: Kyoungmi Kim, Lauren M. Dimapasoc, Gary S. Leiserowitz, Uyen Thao Nguyen, Cynthia C. Williams, Sureyya Ozcan, Suzanne Miyamoto, Carol Stroble, Carlito B. Lebrilla, Sandra L. Taylor, L. Renee Ruhaak
Přispěvatelé: OpenMETU
Rok vydání: 2014
Předmět:
Serum
Oncology
Identification
Glycosylation
endocrine system diseases
Epidemiology
Mass-spectrometry
N-glycans
Carcinoma
Ovarian Epithelial
Bioinformatics
Medical and Health Sciences
Cohort Studies
Neoplasms
Ovarian Epithelial
Disease
Neoplasms
Glandular and Epithelial
Glycan biomarkers
Biomarker discovery
Glycomics
Cancer
Ovarian Neoplasms
screening and diagnosis
Tumor
biology
Glycobiology
Glandular and Epithelial
Middle Aged
female genital diseases and pregnancy complications
Ovarian Cancer
Detection
Female
4.2 Evaluation of markers and technologies
endocrine system
Glycan
medicine.medical_specialty
Annotation
Gynecologic oncology
Discovery
Article
Rare Diseases
Clinical Research
Internal medicine
Carcinoma
medicine
Biomarkers
Tumor
Humans
Prevention
Case-control study
medicine.disease
4.1 Discovery and preclinical testing of markers and technologies
carbohydrates (lipids)
Case-Control Studies
biology.protein
Ovarian cancer
Biomarkers
Zdroj: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, vol 23, iss 4
ISSN: 1538-7755
Popis: Background: Prior studies suggested that glycans were differentially expressed in patients with ovarian cancer and controls. We hypothesized that glycan-based biomarkers might serve as a diagnostic test for ovarian cancer and evaluated the ability of glycans to distinguish ovarian cancer cases from matched controls. Methods: Serum samples were obtained from the tissue-banking repository of the Gynecologic Oncology Group, and included healthy female controls (n = 100), women diagnosed with low malignant potential (LMP) tumors (n = 52), and epithelial ovarian cancers (EOC) cases (n = 147). Cases and controls were matched on age at enrollment within ±5 years. Serum samples were analyzed by glycomics analysis to detect abundance differences in glycan expression levels. A two-stage procedure was carried out for biomarker discovery and validation. Candidate classifiers of glycans that separated cases from controls were developed using a training set in the discovery phase and the classification performance of the candidate classifiers was assessed using independent test samples that were not used in discovery. Results: The patterns of glycans showed discriminatory power for distinguishing EOC and LMP cases from controls. Candidate glycan-based biomarkers developed on a training set (sensitivity, 86% and specificity, 95.8% for distinguishing EOC from controls through leave-one-out cross-validation) confirmed their potential use as a detection test using an independent test set (sensitivity, 70% and specificity, 86.5%). Conclusion: Formal investigations of glycan biomarkers that distinguish cases and controls show great promise for an ovarian cancer diagnostic test. Further validation of a glycan-based test for detection of ovarian cancer is warranted. Impact: An emerging diagnostic test based on the knowledge gained from understanding the glycobiology should lead to an assay that improves sensitivity and specificity and allows for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev; 23(4); 611–21. ©2014 AACR.
Databáze: OpenAIRE
Externí odkaz: